You are here: Industry Insights > Amgen

News List

Amgen to Acquire Teneobio for $900M contractpharma
July 29, 2021
Includes Teneobio's bispecific and multispecific antibody technologies, heavy-chain only platform and T-cell engager platform.
Tezepelumab Granted Priority Review By U.S. FDA drugs
July 15, 2021
Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) and granted Priority Review for tezepelumab in the treatment of asthma.
FDA grants priority review to BLA for AstraZeneca-Amgen’s tezepelumab pharmaceutical-technology
July 09, 2021
The US Food and Drug Administration (FDA) has granted priority review to biologics license application (BLA) for AstraZeneca and Amgen’s experimental drug, tezepelumab, for asthma treatment.
Amgen to build new assembly and final packaging facility in Ohio prnewswire
July 05, 2021
Amgen will spend $365 million to build a new assembly and final packaging manufacturing facility in New Albany, Ohio, the biotech has announced.
deCODE genetics: Predicting the probability of death prnasia
June 18, 2021
Scientists from deCODE genetics have developed a predictor based on protein measurements in blood samples that predicts the time to all-cause death better than traditional risk factors.
Novartis cedes US operations for migraine drug Aimovig to Amgen firstwordpharma
June 17, 2021
Novartis will transfer previously shared US business operations for the anti-CGRP migraine therapy Aimovig (erenumab) to its partner Amgen, the companies confirmed to FirstWord Pharma on Wednesday.
Amgen’s KRAS inhibitor Lumakras scores positive overall survival data pharmatimes
June 08, 2021
Amgen has presented new data on overall survival (OS) for its KRAS inhibitor Lumakras in previously treated non-small cell lung cancer (NSCLC) at the 2021 American Society of Clinical Oncology (ASCO) annual meeting.
Amgen and Kyowa Kirin to Jointly Develop and Commercialize KHK4083, a Phase 3-Ready, Potential First-In-Class Treatment for Atopic Dermatitis prnasia
June 02, 2021
Amgen and Kyowa Kirin Co., Ltd. announced an agreement to jointly develop and commercialize KHK4083, which is Kyowa Kirin's potential first-in-class, Phase 3-ready anti-OX40 fully human monoclonal antibody in development for the treatment of ...
Amgen and Kyowa Kirin agree to jointly develop eczema med pharmatimes
June 02, 2021
Amgen and Kyowa Kirin have signed an agreement to jointly develop and commercialise KHK4083, a monoclonal antibody (mAb) in development for the treatment of atopic dermatitis – the most common form of eczema.
deCODE genetics - Rounding off the human genome prnasia
May 11, 2021
In a study published , scientists at deCODE Genetics demonstrate for the first time how long-read DNA sequencing can be applied at population scale to unravel large structural variants that associate with human disease and other traits.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 22 23 Next page